Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Summary

Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.

Timeline

Start

2002-04

Primary completion

2003-08

Completion

2004-06

Outcome

Met primary endpoint

registry analysis (other test); CX516 vs Placebo; p <.05; Mean Difference (Final Values) 5; t-test, 2 sided NCT00040443 ↗

Drugs

Indications